Article Text

Download PDFPDF
Targeting drug-eluting stents to lesions at high risk of restenosis: a flawed approach?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: Drs Gunn and Morton have accepted sponsorship from Boston Scientific Corporation, manufacturers of the Taxus stent, for attendance at scientific meetings.